Key facts
- This page summarizes Richard N. Kender's Form 4 filing for Seres Therapeutics, Inc. (MCRB).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 10 Jul 2026, 16:15.
Richard N. Kender - 08 Jul 2026 Form 4 Insider Report for Seres Therapeutics, Inc. (MCRB)
- Reporting relationship
- Interim Chief Executive Officer, Director
- Issuer ticker
- MCRB
- Reported as of
- 08 Jul 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Jul 2026, 16:15:13 UTC
- Prior SEC filing
- 06 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas J. DesRosier, Attorney-in-Fact for Richard N. Kender
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Richard N. Kender filed Form 4 for Seres Therapeutics, Inc. (MCRB) on 10 Jul 2026.
Change
- Previous filing in this sequence was filed on 06 Mar 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001381205
Primary reporting owner
Kender Richard N
- Relationship
- Interim Chief Executive Officer, Director
- Address
- C/O SERES THERAPEUTICS, INC., 101 CAMBRIDGE PARK DRIVE, CAMBRIDGE
- Signature
- /s/ Thomas J. DesRosier, Attorney-in-Fact for Richard N. Kender
- Signature date
- 10 Jul 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MCRB
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- Shares
- +50,000
- Change %
- Price
- $0.000000*
- Shares after
- 50,000
- Date
- 08 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $9.13
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option vests and becomes exercisable in 36 equal monthly installments following the March 2, 2026 vesting commencement date.
SEC remarks
Interim Chief Executive Officer